04:44 AM EDT, 06/26/2025 (MT Newswires) -- (Updates with response from Novo Nordisk ( NVO ) in the fifth and sixth paragraphs and latest share price movement the seventh paragraph.)

Novo Nordisk ( NVO ) is under investigation by Spain's ministry of health over its website communications on its weight-loss drug, it emerged Wednesday.

The Spanish government body said the communications on the website "could be considered as covert advertising of prescription drugs, which is prohibited by current legislation," according to a translation of a June 19 statement.

The ministry said it has sent Novo Nordisk ( NVO ) a request for clarification.

"Although no pharmacological treatment is explicitly mentioned, the ministry considers that all the content could constitute a form of indirect advertising of medicines subject to medical prescription," the ministry said.

Novo Nordisk ( NVO ) said in an e-mail to MT Newswires that its "Obesidad Sin Filtros" campaign is an awareness initiative developed with Spanish medical societies and patient organizations.

"We have always collaborated with the National Health System and will continue to do so," the company said. "We are in a good active dialogue with the authorities and immediately responded to their questions. We have shared all documentation required by the Ministry of Health that demonstrates our commitment to comply with the regulations on health information and advertising."

Shares of the company fell 4.8% Wednesday, but were up slightly in recent premarket activity Thursday.